Core Viewpoint - The report from CMB International highlights that 3SBio's partner has significantly accelerated the overseas clinical development of SSGJ-707 (PF-4404), with Pfizer recently disclosing plans to focus on speed, breadth, and depth in its development [1] Group 1: Clinical Development - 3SBio's partner has accelerated the overseas clinical development of SSGJ-707 (PF-4404) [1] - Pfizer's recent disclosure indicates a strategic focus on enhancing the speed, breadth, and depth of the drug's development [1] Group 2: Business Strategy - 3SBio announced plans to spin off its consumer pharmaceutical business, Mandi International, for a listing on the Hong Kong Stock Exchange [1] - Post-spin-off, 3SBio will no longer hold any equity in Mandi International, which is expected to generate short-term investment returns and allow the company to focus on its core prescription and innovative drug business [1] Group 3: Financial Outlook - CMB International has raised its target price for 3SBio to HKD 39.5 and maintains a "Buy" rating along with a sector focus recommendation [1]
大行评级丨交银国际：上调三生制药目标价至39.5港元 维持“买入”评级和行业重点推荐